• NeurAxis published its annual report (Form 10-K) with FY results showing net sales of USD 3.57 million, up 32.9%.
• Gross profit was USD 3.01 million and gross margin was 84.2%, down 2.3 percentage points, attributed to higher discounting in financial assistance programs and expired RED inventory.
• Net loss was USD 7.8 million, down 5.4%, while operating loss was USD 7.83 million, up 9.4% on higher selling and general and administrative expenses.
• Selling expenses rose 55.2% to USD 2.28 million, driven by higher commissions, incremental sales and marketing headcount, and increased advertising tied to the Jan. 1, 2026 effective date of IB-Stim’s new Category I CPT code.
• Cash and cash equivalents were USD 4.97 million, and management said existing cash at the time of filing is expected to be sufficient to meet anticipated operating needs only before the end of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeurAxis Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-011505), on March 19, 2026, and is solely responsible for the information contained therein.